• Immunic positioned vidofludimus calcium (IMU-838) as its lead oral multiple sclerosis candidate, combining Nurr1 activation with selective DHODH inhibition.
• Phase 3 ENSURE-1 and ENSURE-2 relapsing MS trials fully enrolled with 2,221 patients; top-line data expected by year-end 2026.
• U.S. NDA submission targeted for mid-2027; potential U.S. regulatory approval projected in 2028.
• Progressive MS expansion framed around Phase 2 CALLIPER signals on disability measures; Phase 3 program described as in preparation for later in 2026.
• Funding expected into late 2027; U.S. intellectual property protection expected through 2044.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.